	US 12,252,550 B2
	Antibodies that bind to C1S and uses thereof
Vahe Bedian, Waltham, MA (US)
Assigned to DIANTHUS THERAPEUTICS OPCO, INC., New York, NY (US)
Filed by DIANTHUS THERAPEUTICS OpCo, INC., New York, NY (US)
Filed on May 20, 2022, as Appl. No. 17/749,362.
Claims priority of provisional application 63/201,952, filed on May 20, 2021.
Prior Publication US 2022/0380483 A1, Dec. 1, 2022
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01); A61P 7/00 (2006.01); C07K 16/18 (2006.01)

CPC C07K 16/40 (2013.01) [A61P 7/00 (2018.01); A61K 2039/505 (2013.01); C07K 16/18 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01)]

21 Claims

1. An antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, a HCDR2, and a HCDR3; and the light chain variable region comprises a LCDR1, a LCDR2, and a LCRD3, and wherein:

the HCDR1 comprises the amino acid sequence of SEQ ID NO: 32;

the HCDR2 comprises the amino acid sequence of SEQ ID NO: 33;

the HCDR3 comprises the amino acid sequence of SEQ ID NO: 17;

the LCDR1 comprises the amino acid sequence of SEQ ID NO: 34;

the LCDR2 comprises the amino acid sequence of SEQ ID NO: 35; and

the LCDR3 comprises the amino acid sequence of SEQ ID NO: 36.